You are here: Industry Insights > GW Pharma

News List

GW Pharma’s Epidyolex scores new EU indication pharmatimes
April 22, 2021
GW Pharmaceuticals’ Epidyolex has received approval from the European Commission (EC) for the treatment of seizures associated with tuberous sclerosis complex (TSC) – its third indication in Europe.
GW Pharma regains Sativex rights in UK pharmatimes
March 06, 2020
GW Pharmaceuticals has regained the rights to the commercialisation of Sativex (nabiximols) in the UK, taking the reins back from Bayer.
GW Pharma's Epidiolex becomes first cannabis-based medicine to be made available in United States pharmafile
November 19, 2018
GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US states. The medication consists of highly-purified
GW Pharma’s Epidiolex nears US launch pharmatimes
September 29, 2018
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified...
GW Pharma and Orchard biggest UK biotech fundraisers in Q1 pharmaphorum
April 11, 2018
The UK biotech sector has enjoyed a ‘solid start’ in early 2018, with GW Pharma and Orchard Therapeutics dominating the funding raised.
GW Pharma unveils new financial head pharmatimes
March 09, 2017
GW Pharma has named Scott Giacobello as chief financial officer (CFO) of the group.